Widened access to diabetes medicines to benefit over 30,000 New Zealanders
Source: PHARMAC Under new eligibility criteria introduced on 1 September, over the next 12 months around 14,000 more people with type 2 diabetes will be able to access funded medicines empagliflozin, empagliflozin with metformin, liraglutide and dulaglutide, with the number increasing to around 31,000 people after five years. Pharmac Chief Medical Officer, Dr David Hughes,…